Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
Embracing patient community recommendations, FDA draft guidance says historically controlled trials may support efficacy in some cases.